Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cellectar Biosciences, Inc. (NASDAQ: CLRB).

Full DD Report for CLRB

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLRB)

Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference
MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso, president and chief e...
Source: GlobeNewswire
Date: September, 27 2018 08:30
Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences
NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Dow Jones Industrial Average dropped 0.4 percent to close at 26,385.28, while the S&P 500 ...
Source: ACCESSWIRE IA
Date: September, 27 2018 08:00
Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
MADISON, Wis., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso, president and chief ex...
Source: GlobeNewswire
Date: August, 29 2018 08:30
Premarket Gainers as of 9:05 am (08/20/2018)
SSC +106%  on electric bus deal . More news on: Seven Stars Cloud Group, Inc., Black Box Corporation, China Biologic Products, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 20 2018 09:17
Fractionated Dosing Improves Tolerability and Safety of Cellectar's CLR 131 in R/R Multiple Myeloma Patients
Positive Results from Cohort 5 of Phase 1b Trial Company Intends to Initiate a Sixth Cohort and Transition Ongoing Phase 2 Trial to a Fractionated Dose MADISON, Wis., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical co...
Source: GlobeNewswire
Date: August, 20 2018 08:30
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The ...
Source: SeekingAlpha
Date: August, 14 2018 08:58
Premarket Gainers as of 9:05 am (08/13/2018)
ABIL +44% . More news on: Ability Inc., Nielsen Holdings N.V., Xenetic Biosciences, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 13 2018 09:20
Cellectar's CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing's Sarcoma
MADISON, Wis., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA...
Source: GlobeNewswire
Date: August, 13 2018 08:00
Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update
MADISON, Wis., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB)(“Cellectar or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reporte...
Source: GlobeNewswire
Date: August, 10 2018 08:00
Your Daily Pharma Scoop: Theravance Positive, Denali Encouraging, Redhill Clarifies Data
Stocks in News: TBPH, DNLI Theravance's TD-9855 shows positive effect in low blood pressure disorder study Theravance Biopharma ( TBPH ) reported positive data of a four-week data from a Phase 2 clinical trial of TD-9855. The candidate is an once-daily norepinephrine and serotonin reup...
Source: SeekingAlpha
Date: August, 03 2018 00:56

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-132.292.23882.29722.2126,420
2018-12-122.072.312.33022.0688,841
2018-12-112.452.172.752.06875,600
2018-12-102.132.232.302.1243,479
2018-12-072.192.162.192.1138,865

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-132,6005,04751.5158Short
2018-12-1214,04030,44346.1190Short
2018-12-11100,340176,94956.7056Short
2018-12-107,91912,18065.0164Short
2018-12-073,87610,40137.2656Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLRB.


About Cellectar Biosciences, Inc. (NASDAQ: CLRB)

Logo for Cellectar Biosciences, Inc. (NASDAQ: CLRB)

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether PLE platform technology as a targeted delivery and retention vehicle, Cellectar s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I CLR is a small molecule, broad spectrum, cancer targeted PET imaging agent. A Phase II trial evaluating I CLR in glioblastoma is expected to be completed in . Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across solid tumor indications. I CLR is a small molecule, broad spectrum, cancer targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose escalation trial of I CLR in patients with advanced solid tumors is anticipated in the first quarter of . CLR is a preclinical, cancer targeted, non radioactive optical imaging agent for intraoperative tumor margin illumination and non invasive tumor imaging. For additional information please visit www.cellectar.com

 

Contact Information

 

 

Current Management

  • Simon Pedder / Acting CEO
  • J. Patrick Genn / VP, Business Development
  • Chad J. Kolean / VP, Fin., CFO, Treasurer
  • Kathryn McNeil / VP, Investor Relations and Corporate Affairs
  • Stephen A. Hill / Chairman
  • Paul Berns /
  • John Neis /
  • Jamey P. Weichert /

Current Share Structure

     


    Recent Filings from (NASDAQ: CLRB)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 11 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 11 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 09 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 02 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 23 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 17 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 16 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 16 2018
    Preliminary proxy statement providing notification matters to be brought to a vote
    Filing Type: PRE 14AFiling Source: edgar
    Filing Date: April, 13 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 04 2018

     

     


    Daily Technical Chart for (NASDAQ: CLRB)

    Daily Technical Chart for (NASDAQ: CLRB)


    Stay tuned for daily updates and more on (NASDAQ: CLRB)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: CLRB)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLRB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CLRB and does not buy, sell, or trade any shares of CLRB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/